Institutional members access full text with Ovid®

Share this article on:

Usefulness of Contrast-Enhanced Magnetic Resonance Angiography for Follow-Up of Coil Embolization With the Enterprise Stent for Cerebral Aneurysms

Takayama, Katsutoshi MD, PhD; Taoka, Toshiaki MD, PhD; Nakagawa, Hiroyuki MD, PhD; Myouchin, Kaoru MD; Wada, Takeshi MD; Sakamoto, Masahiko MD, PhD; Fukusumi, Akio MD, PhD; Iwasaki, Satoru MD, PhD; Kurokawa, Shinichiro MD, PhD; Kichikawa, Kimihiko MD, PhD

Journal of Computer Assisted Tomography: September/October 2011 - Volume 35 - Issue 5 - pp 568-572
doi: 10.1097/RCT.0b013e31822bd498
Neuroimaging

Objective: The aim of this study was to determine the feasibility and usefulness of contrast-enhanced magnetic resonance angiography (CE-MRA) and 3-dimensional (3D) time-of-flight (TOF) MRA for follow-up of intracranial aneurysms treated using the Enterprise stent.

Methods: Five aneurysm cases using the Enterprise stent were prospectively analyzed and were followed up with CE-MRA, 3D TOF MRA, and digital subtraction angiography (DSA). Depictions of parent artery lumen and the aneurysm neck with 3D TOF MRA and CE-MRA were compared with those of DSA.

Results: In all cases, on 3D TOF MRA, it was difficult to evaluate the parent artery lumen and aneurysm neck owing to the significant artifacts from the stent. Contrast-enhanced MRA sufficiently demonstrated parent artery lumen and aneurysm neck distinctly and as clear as DSA did in all cases.

Conclusions: For follow-up after coiling with an Enterprise stent, CE-MRA may be necessary to avoid susceptibility artifacts caused by the stent.

From the *Department of Radiology and Interventional Neuroradiology, Ishinkai Yao General Hospital, Osaka; †Department of Radiology, Nara Medical University, Nara; and ‡Department of Neurosurgery, Ishinkai Yao General Hospital, Osaka, Japan.

Received for publication May 18, 2011; accepted June 30, 2011.

Reprints: Katsutoshi Takayama, MD, PhD, Department of Radiology and Interventional Neuroradiology, Ishinkai Yao General Hospital, 1-41 Numa Yao, Osaka 581-0036, Japan (e-mail: takayamaneuroivs@par.odn.ne.jp).

The authors declare that they have no conflict of interest.

Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.